NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives $11.90 Consensus Target Price from Brokerages
by Jessica Moore · The Cerbat GemNeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) has been given a consensus recommendation of “Hold” by the five ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $11.90.
Several equities analysts have weighed in on the company. JonesTrading started coverage on NeuroOne Medical Technologies in a research note on Monday, March 2nd. They set a “buy” rating and a $9.00 price objective on the stock. Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. Finally, Zacks Research lowered NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th.
Get Our Latest Analysis on NeuroOne Medical Technologies
NeuroOne Medical Technologies Stock Down 3.2%
Shares of NMTC opened at $4.61 on Tuesday. The business’s fifty day moving average is $4.48 and its 200 day moving average is $4.60. NeuroOne Medical Technologies has a 12-month low of $3.27 and a 12-month high of $6.96. The stock has a market cap of $38.82 million, a P/E ratio of -4.52 and a beta of 0.63.
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The business had revenue of $2.89 million for the quarter, compared to analysts’ expectations of $2.47 million. On average, analysts expect that NeuroOne Medical Technologies will post -0.72 EPS for the current year.
Insider Buying and Selling
In related news, insider David J. Wambeke bought 166,666 shares of the business’s stock in a transaction on Sunday, March 1st. The stock was acquired at an average price of $4.02 per share, for a total transaction of $669,997.32. Following the purchase, the insider directly owned 166,666 shares in the company, valued at $669,997.32. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 2,438 shares of company stock valued at $11,702. 11.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies during the 1st quarter valued at about $84,000. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies during the 2nd quarter valued at about $51,000. Focus Financial Network Inc. bought a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter valued at about $31,000. Vanguard Group Inc. boosted its position in shares of NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter valued at about $88,000. Institutional investors own 16.07% of the company’s stock.
NeuroOne Medical Technologies Company Profile
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.